"...significantly improved tumor free long-term survival and apparent cures in 35%…"
Peregrine's proprietary anti-PS tech is already producing cancer cures in pre-clinical. Dr. Brekken says to watch for 200%-300% increases in responses when anti-PS is used in combination with downstream immunotherapies. Those combo studies were started in June 2013, and should soon be seen in posters, and a possible phase I immunotherapy combination trial before year end. My guess is that the phase I trial would be a collaboration with a BP.